CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma

British Journal of Haematology

Volumn 179, Issue 1, 2017, Pages 36-49

  Waldschmidt, Johannes M ^a   Simon, Anna ^a   Wider, Dagmar ^a   Müller, Stefan J ^a   Follo, Marie ^a   Ihorst, Gabriele ^a   Decker, Sarah ^a   Lorenz, Joschka ^a   Chatterjee, Manik ^b   Azab, Abdel K ^c   Duyster, Justus ^a   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adhesion molecules; drug resistance; multiple myeloma; stem cell mobilizing homing; stroma cells

Indexed keywords

ALPHA4 INTEGRIN; BORTEZOMIB; CARFILZOMIB; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CYTOTOXIC AGENT; DEXAMETHASONE; HERMES ANTIGEN; NOX A 12; OLAPTESED PEGOL; PLERIXAFOR; POMALIDOMIDE; STROMAL CELL DERIVED FACTOR 1; VORINOSTAT; ANTINEOPLASTIC AGENT; APTAMER; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR; CXCR7 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; MITOGEN ACTIVATED PROTEIN KINASE 1; NOX-A12; OLIGOPEPTIDE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW STROMA CELL; CANCER CELL; CANCER RESISTANCE; CELL ADHESION; CELL ADHESION MEDIATED DRUG RESISTANCE; CELL FUNCTION; CHEMOSENSITIZATION; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; BONE MARROW CELL; CANCER STAGING; CHROMOSOME ABERRATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; STROMA CELL; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BIOMARKERS; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; CHEMOKINE CXCL12; CHROMOSOME ABERRATIONS; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MULTIPLE MYELOMA; NEOPLASM STAGING; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RECEPTORS, CXCR; STROMAL CELLS;

EID: 85021728553     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14807     Document Type: Article

References (56)

1. Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U.K., Pitsillides, C.M., Spencer, J.A., Kimlinger, T., Ghobrial, J.M., Jia, X., Lu, G., Timm, M., Kumar, A., Côté, D., Veilleux, I., Hedin, K.E., Roodman, G.D., Witzig, T.E., Kung, A.L., Hideshima, T., Anderson, K.C., Lin, C.P. & Ghobrial, I.M. (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood, 109, 2708–2717.
2. Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J. & Kirk, C.J. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical Cancer Research, 17, 2734–2743.
3. Azab, A.K., Runnels, J.M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A.L., Alt, C., Burwick, N., Roccaro, A.M., Ngo, H.T., Farag, M., Melhem, M.R., Sacco, A., Munshi, N.C., Hideshima, T., Rollins, B.J., Anderson, K.C., Kung, A.L., Lin, C.P. & Ghobrial, I.M. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 113, 4341–4351.
4. Azab, A.K., Sahin, I., Moschetta, M., Mishima, Y., Burwick, N., Zimmermann, J., Romagnoli, B., Patel, K., Chevalier, E., Roccaro, A.M. & Ghobria, I.M. (2014) CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood, 124, 1905–1914.
5. Berahovich, R.D., Penfold, M.E.T. & Schall, T.J. (2010) Nonspecific CXCR7 antibodies. Immunology Letters, 133, 112–114.
6. Bhutani, M., Lee, M., Tomita, Y., Lee, S., Frosch, A., Carlsten, M., Steinberg, S.M., Korde, N., Landgren, O. & Trepel, J.B. (2014) Early biomarkers of response to carfilzomib in multiple myeloma (MM): modulation of CXCR4 and induction of autophagy. Journal of Clinical Oncology (Suppl), abstr, e19572.
7. Burger, J.A. & Gribben, J.G. (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Seminars in Cancer Biology, 24, 71–81.
8. Burns, J.M., Summers, B.C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M.E.T., Sunshine, M.J., Littman, D.R., Kuo, C.J., Wei, K., McMaster, B.E., Wright, K., Howard, M.C. & Schall, T.J. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. Journal of Experimental Medicine, 203, 2201–2213.
9. van de Donk, N.W.C., Moreau, P., Plesner, T., Palumbo, A., Gay, F., Laubach, J.P., Malavasi, F., Avet-Loiseau, H., Mateos, M.V., Sonneveld, P., Lokhorst, H.M. & Richardson, P.G. (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 127, 681–695.
10. Engelhardt, M., Winkler, J., Waller, C., Lange, W., Mertelsmann, R. & Henschler, R. (1997) Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplantation, 19, 529–537.
11. Engelhardt, M., Mackenzie, K., Drullinsky, P., Silver, R.T. & Moore, M.A. (2000) Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Research, 60, 610–617.
12. Engelhardt, M., Terpos, E., Kleber, M., Gay, F., Wäsch, R., Morgan, G., Cavo, M., van de Donk, N., Beilhack, A., Bruno, B., Johnsen, H.E., Hajek, R., Driessen, C., Ludwig, H., Beksac, M., Boccadoro, M., Straka, C., Brighen, S., Gramatzki, M., Larocca, A., Lokhorst, H., Magarotto, V., Morabito, F., Dimopoulos, M.A., Einsele, H., Sonneveld, P. & Palumbo, A.; European Myeloma Network. (2014) European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 99, 232–242.
13. Fricker, S.P., Anastassov, V., Cox, J., Darkes, M.C., Grujic, O., Idzan, S.R., Labrecque, J., Lau, G., Mosi, R.M., Nelson, K.L., Qin, L., Santucci, Z. & Wong, R.S.Y. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochemical Pharmacology, 72, 588–596.
14. Frigyesi, I., Adolfsson, J., Ali, M., Christophersen, M.K., Johnsson, E., Turesson, I., Gullberg, U., Hansson, M. & Nilsson, B. (2014) Robust isolation of malignant plasma cells in multiple myeloma. Blood, 123, 1336–1340.
15. Gay, F., Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., Pezzatti, S., Ferrari, S., Liberati, A.M., Oliva, S., Patriarca, F., Offidani, M., Omedé, P., Montefusco, V., Petrucci, M.T., Giuliani, N., Passera, R., Pietrantuono, G., Boccadoro, M., Corradini, P. & Palumbo, A. (2013) Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 122, 1376–1383.
16. Ghobrial, I., Laubach, J., Shain, K., Baz, R., Boswell, E.N., Henrick, P., Azab, A.K., Hanlon, D., Chuma, S., Leblebjian, H., Noonan, K., MacNabb, M., Warren, D., Armand, P., Paba-Prada, C., Munshi, N., Schlossman, R.L., Anderson, K.C. & Richardson, P.G. (2013) Phase I/II trial of plerixafor and bortezomib as a chemosensitization strategy in relapsed or relapsed/refractory multiple myeloma. Blood, 122, 1947.
17. Greil, C., Kiote-Schmidt, C., Fink, G., Ihorst, G., Hildenbeutel, S., Bosse, R., Duyster, J., Engelhardt, M. & Wäsch, R. (2017) Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. Leukaemia & Lymphoma, 58, 1849–1858.
18. Heckmann, D., Maier, P., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S. & Allgayer, H. (2013) CXCR4 expression and treatment with SDF-1α or plerixafor modulate proliferation and chemosensitivity of colon cancer cells. Translational Oncology, 6, 124–132.
19. Herndon, T.M., Deisseroth, A., Kaminskas, E., Kane, R.C., Koti, K.M., Rothmann, M.D., Habtemariam, B., Bullock, J., Bray, J.D., Hawes, J., Palmby, T.R., Jee, J., Adams, W., Mahayni, H., Brown, J., Dorantes, A., Sridhara, R., Farrell, A.T. & Pazdur, R. (2013) U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clinical Cancer Research, 19, 4559–4563.
20. Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N.Y., Wierda, W.G., Keating, M.J., Kruschinski, A. & Burger, J.A. (2014) The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood, 123, 1032–1039.
21. Hurchla, M.A., Garcia-Gomez, A., Hornick, M.C., Ocio, E.M., Li, A., Blanco, J.F., Collins, L., Kirk, C.J., Piwnica-Worms, D., Vij, R., Tomasson, M.H., Pandiella, A., San Miguel, J.F., Garayoa, M. & Weilbaecher, K.N. (2013) The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia, 27, 430–440.
22. Kim, H.-Y., Hwang, J.-Y., Kim, S.-W., Lee, H.-J., Yun, H.-J., Kim, S. & Jo, D.-Y. (2010) The CXCR4 antagonist AMD3100 has dual effects on survival and proliferation of myeloma cells in vitro. Cancer Research and Treatment, 42, 225–234.
23. Korde, N. & Maric, I. (2011) Myelomagenesis: capturing early microenvironment changes. Seminars in Hematology, 48, 13–21.
24. Kurtova, A.V., Tamayo, A.T., Ford, R.J. & Burger, J.A. (2009) Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood, 113, 4604–4613.
25. Lawasut, P., Chauhan, D., Laubach, J., Hayes, C., Fabre, C., Maglio, M., Mitsiades, C., Hideshima, T., Anderson, K.C. & Richardson, P.G. (2012) New proteasome inhibitors in myeloma. Current Hematologic Malignancy Reports, 7, 258–266.
26. Liu, W., Henry, J., Meyer, B., Bartlett, J.B., Dalgleish, A.G. & Galustian, C. (2009) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer, 101, 803-812.
27. ® Olaptesed Pegol (NOX-A12) in combination with bortezomib and dexamethasone in patients with multiple myeloma. Blood, 124, 2111.
28. Ludwig, H., Weisel, K., Petrucci, M.T., Leleu, X., Cafro, A.M., Garderet, L., Leitgeb, C., Foa, R., Greil, R., Yakoub-Agha, I., Zboralski, D., Vauléon, S., Dümmler, T., Beyer, D., Kruschinski, A., Riecke, K., Baumann, M. & Engelhardt, M. (2017) Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a phase IIa study. Leukemia, 31, 997–1000.
29. Mazzinghi, B., Ronconi, E., Lazzeri, E., Sagrinati, C., Ballerini, L., Angelotti, M.L., Parente, E., Mancina, R., Netti, G.S., Becherucci, F., Gacci, M., Carini, M., Gesualdo, L., Rotondi, M., Maggi, E., Lasagni, L., Serio, M., Romagnani, S. & Romagnani, P. (2008) Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. Journal of Experimental Medicine, 205, 479–490.
30. McCarthy, P.L. (2013) Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Journal of the National Comprehensive Cancer Network, 11, 35–42.
31. Menu, E., Asosingh, K., Indraccolo, S., De Raeve, H., Van Riet, I., Van Valckenborgh, E., Vande Broek, I., Van de Broek, I., Fujii, N., Tamamura, H., Van Camp, B. & Vanderkerken, K. (2006) The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica, 91, 605–612.
32. Miao, Z., Luker, K.E., Summers, B.C., Berahovich, R., Bhojani, M.S., Rehemtulla, A., Kleer, C.G., Essner, J.J., Nasevicius, A., Luker, G.D., Howard, M.C. & Schall, T.J. (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proceedings of the National Academy of Sciences of the United States of America, 104, 15735–15740.
33. Noborio-Hatano, K., Kikuchi, J., Takatoku, M., Shimizu, R., Wada, T., Ueda, M., Nobuyoshi, M., Oh, I., Sato, K., Suzuki, T., Ozaki, K., Mori, M., Nagai, T., Muroi, K., Kano, Y., Furukawa, Y. & Ozawa, K. (2009) Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene, 28, 231–242.
34. Palumbo, A. & Anderson, K. (2011) Multiple myeloma. New England Journal of Medicine, 364, 1046–1060.
35. Papandreou, C.N., Daliani, D.D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C.S., Millikan, R.E., Tu, S.-M., Pagliaro, L., Kim, J., Adams, J., Elliott, P., Esseltine, D., Petrusich, A., Dieringer, P., Perez, C. & Logothetis, C.J. (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. Journal of Clinical Oncology, 22, 2108–2121.
36. Parlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., Micklem, D.R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K.D. & Bennett, M.K. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 114, 3439–3447.
37. Pessoa de Magalhães, R.J., Vidriales, M.-B., Paiva, B., Fernandez-Gimenez, C., García-Sanz, R., Mateos, M.-V., Gutierrez, N.C., Lecrevisse, Q., Blanco, J.F., Hernández, J., de las Heras, N., Martinez-Lopez, J., Roig, M., Costa, E.S., Ocio, E.M., Perez-Andres, M., Maiolino, A., Nucci, M., De La Rubia, J., Lahuerta, J.-J., San-Miguel, J.F. & Orfao, A.; Spanish Myeloma Group (GEM), Grupo Castellano-Leones de Gammapatias Monoclonales, Cooperative Study Groups. (2013) Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica, 98, 79–86.
38. Puchert, M. & Engele, J. (2014) The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets. Cell and Tissue Research, 355, 239–253.
39. Reagan, M.R., Mishima, Y., Glavey, S.V., Zhang, Y., Manier, S., Lu, Z.N., Memarzadeh, M., Zhang, Y., Sacco, A., Aljawai, Y., Shi, J., Tai, Y.-T., Ready, J.E., Kaplan, D.L., Roccaro, A.M. & Ghobrial, I.M. (2014) Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood, 124, 3250–3259.
40. Roccaro, A.M., Sacco, A., Purschke, W.G., Moschetta, M., Buchner, K., Maasch, C., Zboralski, D., Zöllner, S., Vonhoff, S., Mishima, Y., Maiso, P., Reagan, M.R., Lonardi, S., Ungari, M., Facchetti, F., Eulberg, D., Kruschinski, A., Vater, A., Rossi, G., Klussmann, S. & Ghobrial, I.M. (2014) SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Reports, 9, 118–128.
41. Roccaro, A.M., Mishima, Y., Sacco, A., Moschetta, M., Tai, Y.-T., Shi, J., Zhang, Y., Reagan, M.R., Huynh, D., Kawano, Y., Sahin, I., Chiarini, M., Manier, S., Cea, M., Aljawai, Y., Glavey, S., Morgan, E., Pan, C., Michor, F., Cardarelli, P., Kuhne, M. & Ghobrial, I.M. (2015) CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Reports, 12, 622–635.
42. Sánchez-Martín, L., Sánchez-Mateos, P. & Cabañas, C. (2013) CXCR7 impact on CXCL12 biology and disease. Trends in Molecular Medicine, 19, 12–22.
43. Schüler, J., Ewerth, D., Waldschmidt, J., Wäsch, R. & Engelhardt, M. (2013) Preclinical models of multiple myeloma: a critical appraisal. Expert Opinion on Biological Therapy, 13, S111–S123.
44. Shay, K.P., Wang, Z., Xing, P.-X., McKenzie, I.F.C. & Magnuson, N.S. (2005) Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Molecular Cancer Research, 3, 170–181.
45. Smith, M.A. & Houghton, P. (2013) A proposal regarding reporting of in vitro testing results. Clinical Cancer Research, 19, 2828–2833.
46. Stessman, H.A.F., Mansoor, A., Zhan, F., Janz, S., Linden, M.A., Baughn, L.B. & Van Ness, B. (2013) Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia, 27, 2075–2077.
47. Tarnowski, M., Liu, R., Wysoczynski, M., Ratajczak, J., Kucia, M. & Ratajczak, M.Z. (2010) CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. European Journal of Haematology, 85, 472–483.
48. Tian, Z., Zhao, J., Tai, Y.-T., Amin, S.B., Hu, Y., Berger, A.J., Richardson, P., Chauhan, D. & Anderson, K.C. (2012) Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood, 120, 3958–3967.
49. Touzeau, C., Le Gouill, S., Mahé, B., Boudreault, J.S., Gastinne, T., Blin, N., Caillon, H., Dousset, C., Amiot, M. & Moreau, P. (2017) Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica, 102, e112–e114.
50. Udi, J., Schüler, J., Wider, D., Ihorst, G., Catusse, J., Waldschmidt, J., Schnerch, D., Follo, M., Wäsch, R. & Engelhardt, M. (2013) Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. British Journal of Haematology, 161, 104–116.
51. Vande Broek, I., Vanderkerken, K., Van Camp, B. & Van Riet, I. (2008) Extravasation and homing mechanisms in multiple myeloma. Clinical & Experimental Metastasis, 25, 325–334.
52. Waldschmidt, J., Keller, A., Wider, D., Jakobs, D., Möller, M., Reinhardt, H., Pantic, M., Grishina, O., Ihorst, G., May, A.M., Frey, A., Kohlweyer, U., Duyster, J., Jung, M., Engelhardt, M. & Wäsch, R. (2015) Results of an open, non-comparative, phase I/II investigator initiated trial (IIT) in relapsed or refractory multiple myeloma patients using vorinostat, bortezomib, doxorubicin and dexamethasone (VBDD). Blood, 126, 4260.
53. Wang, H., Beaty, N., Chen, S., Qi, C.-F., Masiuk, M., Shin, D.-M. & Morse, H.C. (2012) The CXCR7 chemokine receptor promotes B-cell retention in the splenic marginal zone and serves as a sink for CXCL12. Blood, 119, 465–468.
54. Zhang, W.-B., Navenot, J.-M., Haribabu, B., Tamamura, H., Hiramatu, K., Omagari, A., Pei, G., Manfredi, J.P., Fujii, N., Broach, J.R. & Peiper, S.C. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. Journal of Biological Chemistry, 277, 24515–24521.
55. Zlei, M., Egert, S., Wider, D., Ihorst, G., Wäsch, R. & Engelhardt, M. (2007) Characterization of in vitro growth of multiple myeloma cells. Experimental Hematology, 35, 1550–1561.
56. Zoughlami, Y., Voermans, C., Brussen, K., van Dort, K.A., Kootstra, N.A., Maussang, D., Smit, M.J., Hordijk, P.L. & van Hennik, P.B. (2012) Regulation of CXCR4 conformation by the small GTPase Rac1: implications for HIV infection. Blood, 119, 2024–2032.